Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge.

ABSTRACT: Significant concerns have arisen over the past 3 y from the increased global spread of the mosquito-borne flavivirus, Zika. Accompanying this spread has been an increase in cases of the devastating birth defect microcephaly as well as of Guillain-Barré syndrome in adults in many affected countries. Currently there is no vaccine or therapy for this infection; however, we sought to develop a combination approach that provides more rapid and durable protection than traditional vaccination alone. A novel immune-based prophylaxis/therapy strategy entailing the facilitated delivery of a synthetic DNA consensus prME vaccine along with DNA-encoded anti-ZIKV envelope monoclonal antibodies (dMAb) were developed and evaluated for antiviral efficacy. This immediate and persistent protection strategy c

SUBMITTER: Choi H 

PROVIDER: S-EPMC7227701 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature